β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial-Reference-Cited by-同舟云学术

β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial

Published:2019-04 Issue:10181 Volume:393 Page:1597-1608
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Villanueva Càndid,Albillos Agustín,Genescà Joan,Garcia-Pagan Joan C,Calleja José L,Aracil Carles,Bañares Rafael,Morillas Rosa M,Poca María,Peñas Beatriz,Augustin Salvador,Abraldes Juan G,Alvarado Edilmar,Torres Ferran,Bosch Jaume

Funder

Instituto de Salud Carlos III

Publisher

Elsevier BV

Subject

General Medicine

Reference29 articles.

1. Liver cirrhosis;Tsochatzis;Lancet,2014

2. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies;D'Amico;J Hepatol,2006

3. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis;Ripoll;Gastroenterology,2007

4. Expanding consensus in portal hypertension. Report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension. Revising consensus in portal hypertension;De Franchis;J Hepatol,2015

5. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis and management: 2016 practice guidance by the American Association for the Study of Liver Diseases;Garcia-Tsao;Hepatology,2017

Cited by 448 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cirrhosis in the tropics;Treatment and Management of Tropical Liver Disease;2025

2. Hepatic immune regulation and sex disparities;Nature Reviews Gastroenterology & Hepatology;2024-09-05

3. Portal hypertension is associated with poorer outcome and clinical liver decompensation in patients with HCC treated with Atezolizumab-Bevacizumab;Digestive and Liver Disease;2024-09

4. EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD);Journal of Hepatology;2024-09

5. Capsule endoscopy in portal hypertension and varices;Portal Hypertension & Cirrhosis;2024-08-28